/PRNewswire/ – Astellas Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka today announced the promotion of James Robinson as president, Americas Operations, for Astellas US LLC, with responsibility for the company’s operations in North and South America, effective April 1, 2016. Robinson previously served as president, Astellas Pharma US, representing the commercial organization in the United States — a role he assumed in 2013.
Robinson will succeed Masao Yoshida, who is retiring in June 2016.
“As a 10-year veteran of Astellas with more than 20 years of healthcare industry experience, Jim’s commitment to operational and commercial excellence has helped Astellas grow dramatically in the Americas,” said Hatanaka. “His deep experience, skills and strong commitment to operating and leading with the highest sense of ethics and compliance will help Astellas stay focused on our global vision to be on the forefront of healthcare change to turn innovative science into value for patients.”
“Astellas is respected for its unwavering focus on supporting patients. This foundational idea is our compass for continued growth in the Americas,” said Robinson. “We will remain committed to serving patients, pursuing operational excellence within the organization and building Astellas’ presence throughout the Americas.”
Robinson joined Astellas in 2005 as the vice president of health systems, responsible for managed markets, reimbursement strategy, state government affairs and government accounts, and has since held positions of increasing responsibility. In 2011, Robinson was named senior vice president, sales and marketing, leading the US organization responsible for sales, marketing, new product planning, market access and commercial operations.
Robinson began his career at Schering-Plough in 1992 as a sales representative, and held positions of increasing responsibility until he was promoted to vice president of hepatitis sales and managed care in 2003. In this position, he led the largest specialty pharmaceutical sales division within Schering-Plough until he joined Astellas.
He serves as chairman of the Pharmaceutical Research and Manufacturers of America State Committee, is a member of the BioScience council for ChicagoNEXT and serves on the board of directors of MATTER. He is member of The Commercial Club of Chicago and is a graduate of DePaul University.
As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.
McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.
AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.